— Why it moved
Why DRMA Stock Spiked and Faded Today — October 15, 2026
Dermata Therapeutics used a 31-patient cosmetic study release to stir up a low-float momentum spike that faded by the closing bell.
What moved DRMA stock
Dermata Therapeutics is a micro-cap biotech focused on dermatological treatments. They dropped a press release showing positive consumer survey feedback from a 31-participant study for their cosmetic skin renewal product. It was light marketing data passed off as clinical progress, but low-float tickers rarely care about the distinction during the initial rush.
The mechanics
A tiny float of 2.9 million shares on a sub-$4 million market cap made an explosive move easy. Over 170 million shares changed hands, flipping the floating supply nearly sixty times over in a single session.
DRMA by the numbers
The alert window
The alert went out in the pre-market at $0.9008 before the stock dropped 16.9% to a low of $0.7488 near the session's start. Traders who held through that early dip had a 100-minute window to cash out as it climbed to a peak of $1.18, giving a 31.0% sellable move.
How DRMA's move ended
The momentum washed out completely by the afternoon. DRMA drifted lower to close at $0.8936, down 0.8% from the alert price as micro-cap dilution realities took back control.
The tell: Small cosmetic survey results are marketing assets, not fundamental biotech catalysts.